Skip to main content
SpringerLink
Log in

Blocking bleeding: reversing anticoagulant therapy

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A new generation of target-specific inhibitors of the coagulation enzymes thrombin and factor Xa has been approved for a number of indications, but the clinical use of these drugs is hindered by the lack of a way to reverse bleeding, should it occur. An antidote to these new oral anticoagulants has now been designed and shows promise in small-animal models of blood loss (pages 446–451).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Lu et al.11 now describe the design and actions of an antidote to target-specific anticoagulants.

Katie Vicari

References

  1. Ansell, J.E. Arch. Intern. Med. 153, 586–596 (1993).

    Article  CAS  Google Scholar 

  2. Thomas, K. A promising drug with a flaw. New York Times (3 November 2012).

  3. Kaatz, S. et al. Am. J. Hematol. 87, S141–S145 (2012).

    Article  CAS  Google Scholar 

  4. Budnitz, D.S., Lovegrove, M.C., Shehab, N. & Richards, C.L. N. Engl. J. Med. 365, 2002–2012 (2011).

    Article  CAS  Google Scholar 

  5. QuarterWatch. http://www.ismp.org/quarterwatch/pdfs/2011Q4.pdf (2012).

  6. Sarode, R. et al. Am. J. Hematol. 87, S146 (2012).

    Article  Google Scholar 

  7. Bauer, K.A. Am. J. Hematol. 87, S119–S126 (2012).

    Article  CAS  Google Scholar 

  8. Dager, W. & Roberts, A. Crit. Care Med. 39 (suppl. 12), 243 (2011).

    Google Scholar 

  9. Garber, S.T., Sivakumar, W. & Schmidt, R.H. J. Neurosurg. 116, 1093–1096 (2012).

    Article  Google Scholar 

  10. Levi, M. Thromb. Haemost. 108, 201–202 (2012).

    Article  CAS  Google Scholar 

  11. Lu, G. et al. Nat. Med. 19, 446–451 (2013).

    Article  CAS  Google Scholar 

  12. Marketwire. http://www.marketwire.com/press-release/portola-initiates-phase-2-study-prt4445-universal-antidote-factor-xa-inhibitor-anticoagulants-1735434.htm (2012).

  13. Rusconi, C.P. et al. Nat. Biotechnol. 22, 1423–1428 (2004).

    Article  CAS  Google Scholar 

  14. Povsic, T.J. et al. Euro. Heart J. published online, http://dx.doi.org/10.1093/eurheartj/ehs232 (2 August 2012).

Download references

Author information

Authors and Affiliations

  1. Jack Ansell is in the Department of Medicine, Lenox Hill Hospital, New York, New York, USA.,

    Jack Ansell

Authors
  1. Jack Ansell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack Ansell.

Ethics declarations

Competing interests

J.A. is a member of the scientific advisory board of and owns equity in Perosphere.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ansell, J. Blocking bleeding: reversing anticoagulant therapy. Nat Med 19, 402–404 (2013). https://doi.org/10.1038/nm.3157

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3157

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation